Search results
Results from the WOW.Com Content Network
Splenic marginal zone lymphoma (SMZL) is a type of marginal zone lymphoma, a cancer made up of B-cells that replace the normal architecture of the white pulp of the spleen. The neoplastic cells are both small lymphocytes and larger, transformed lymphoblasts , and they invade the mantle zone of splenic follicles and erode the marginal zone ...
Extranodal marginal zone lymphomas (EMZLs) are a form of MZL [9] in which malignant marginal zone B-cells initially infiltrate MALT tissues of the stomach (50-70% of all EMZL) or, less frequently, the esophagus, small intestine, large intestine, rectum, conjunctiva of the eye, nasal passages, pharynx, lung bronchi, vulva, vagina, skin, breast, thymus gland, meninges (i.e. membranes) that ...
Lymphoma may present with certain nonspecific symptoms; if the symptoms are persistent, an evaluation to determine their cause, including possible lymphoma, should be undertaken. Lymphadenopathy [ 19 ] [ 20 ] or swelling of lymph nodes, is the primary presentation in lymphoma.
Marginal zone lymphoma (MZL) is a heterogeneous group of indolent B cell lymphomas that arise from the marginal zone of lymphoid tissues. [17] It accounts for 5–10% of all NHL cases, with an annual incidence of 0.4 to 1.0 per 100,000 in Western countries. [ 18 ]
Follicular lymphoma: Splenic marginal zone lymphoma: Nodal marginal zone B cell lymphoma: Mantle cell lymphoma: Hairy cell leukemia: Prolymphocytic leukemia (B cell or T cell) Lymphoplasmacytic lymphoma: Sézary syndrome: Smoldering adult T cell leukemia/lymphoma
Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase "large-cell lymphoma" under "Diffuse large B cell lymphoma". [2] Many other B-cell lymphomas feature large cells: [citation needed] Angiocentric lymphoma; Burkitt's lymphoma; Follicular large-cell lymphoma; Immunoblastic lymphoma
These malignancies appear to have been primarily marginal zone B-cell lymphomas of the splenic marginal zone B-cell, splenic lymphoma/leukemia unclassifiable, hairy cell leukemia, and possibly Waldenström's macroglobulinemia. MBL-MZ requires further studies to evaluate its frequencies, rate of progression to malignancy, and treatment. [6]
The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7] In addition to cure-directed treatment, people can benefit from self-care to manage symptoms.